학술논문
miR-155 expression is associated with chemoimmunotherapy outcome and is modulated by Bruton's tyrosine kinase inhibition with Ibrutinib.
Document Type
Article
Author
Source
Subject
*MICRORNA
*IMMUNOTHERAPY
*PROTEIN-tyrosine kinase inhibitors
*CHRONIC lymphocytic leukemia
*DISEASE progression
*B cells
*
*
*
*
*
Language
ISSN
0887-6924
Abstract
The article discusses the association of miR-155 expression with chemoimmunotherapy outcome modulated by Bruton's tyrosine kinase inhibition with Ibrutinib. It mentions the miR expression profiling in chronic lymphocytic leukemia (CLL) which has been used to identify miR signatures that predict disease progression. It also explores the regulation of B-cell receptor (BCR) pathways to investigate the close association between BCR activation and miR-155 in CLL.